MTPH Midatech Pharma Plc

TIDMMTPH

RNS Number : 6490S

Midatech Pharma PLC

10 March 2023

10 March 2023

Midatech Pharma PLC

("Midatech" or the "Company")

Further re : Notice of General Meeting - Correction of Typographical Errors

Further to the announcement made on 8 March 2023 providing notice of a general meeting (the " GM ") of the Company to be held on 24 March 2023, and the publication and despatch of a circular to shareholders containing notice of the resolutions to be considered at the GM (the " Notice ") and form of proxy (the " Form of Proxy "), the Company announces the following corrections to certain typographical errors identified within the Notice and Form of Proxy:

-- Resolution 4 of the Notice (" Resolution 4 ") refers to a proposed authority to waive pre-emption rights in respect of the allotment authority sought by resolution 2 of the Notice which is limited to an aggregate nominal amount of GBP1,911,169.68. Accordingly, the waiver of pre-emption rights authority sought by Resolution 4 should be an amount of GBP1,911,169.68 (not GBP2,905,400.59 as currently stated in the Notice);

-- Resolution 5 of the Notice (" Resolution 5 ") refers to a proposed authority to waive pre-emption rights in respect of the allotment authority sought by resolution 3 of the Notice which is limited to an aggregate nominal amount of GBP2,300,000.00. Accordingly, the waiver of pre-emption rights authority sought by Resolution 5 should be an amount of GBP2,300,000.00 (not GBP4,200,000 as currently stated in the Notice); and

-- Resolution 4 as described on the Form of Proxy incorrectly states that it is "To authorise grant the Directors authority to allot shares in the Company in connection with the grant of the A Warrants, the B Warrants, the Ladenburg Warrants, the Waiver Warrants and the Pre-Funded Warrants" (which effectively duplicates resolution 2 of the Form of Proxy). In accordance with the resolutions set out in the Notice, resolution 4 of the Form of Proxy should instead state that it is "To disapply statutory pre-emption rights in connection with the grant of the A Warrants, the B Warrants, the Ladenburg Warrants, the Waiver Warrants and the Pre-Funded Warrants".

As such errors are administrative in nature, no new Notice will be published and the aforementioned amendments to Resolution 4 and Resolution 5 will be effected by a motion to be passed at the GM. Furthermore, no new Form of Proxy will be posted to shareholders but a copy of the corrected Form of Proxy will be made available on the Company's website at: www.midatechpharma.com/. Any shareholder who wishes to change any proxy instructions already submitted may do so by submitting a new proxy appointment using the method set out in the notes to the Notice.

 
 For more information, please contact : Midatech Pharma PLC 
 Stephen Stamp, CEO, CFO 
 Tel: +44 (0)29 2048 0180 
 www.midatechpharma.com 
 
 Strand Hanson Limited (Nominated Adviser and Broker) 
 James Dance / Matthew Chandler / Rob Patrick 
 Tel: +44 (0)20 7409 3494 
 
 IFC Advisory Limited (Financial PR and UK Investor Relations) 
 Tim Metcalfe / Graham Herring 
 Tel: +44 (0)20 3934 6630 
 Email: midatech@investor-focus.co.uk 
 
 Edison Group (US Investor Relations) 
  Alyssa Factor 
  Tel: +1 (860) 573 9637 
  Email: afactor@edisongroup.com 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

FURBRGDXGUBDGXG

(END) Dow Jones Newswires

March 10, 2023 12:52 ET (17:52 GMT)

Midatech Pharma (LSE:MTPH)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Midatech Pharma (LSE:MTPH)
Gráfica de Acción Histórica
De May 2023 a May 2024